ZEALAND PHARMA/S (ZEAL) Sets New 1-Year High at $20.92
ZEALAND PHARMA/S (NASDAQ:ZEAL) hit a new 52-week high on Tuesday . The company traded as high as $20.92 and last traded at $20.92, with a volume of 2600 shares changing hands. The stock had previously closed at $20.26.
ZEAL has been the topic of a number of analyst reports. TheStreet upgraded shares of ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th. ValuEngine upgraded shares of ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th. Finally, Zacks Investment Research lowered shares of ZEALAND PHARMA/S from a “buy” rating to a “hold” rating and set a $21.00 price objective on the stock. in a report on Saturday, April 13th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.00.
The firm has a market cap of $611.12 million, a price-to-earnings ratio of 6.98 and a beta of 2.40.
A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. Jane Street Group LLC bought a new stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 25,285 shares of the company’s stock, valued at approximately $320,000. Jane Street Group LLC owned 0.08% of ZEALAND PHARMA/S as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.23% of the company’s stock.
About ZEALAND PHARMA/S (NASDAQ:ZEAL)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.